GlassScriptPhysician profile
Noel C Gardner
NPI 1285655746
$512,253.01
in general payments reported to CMS, 2019-2025
14 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $68K · 2021: $68K · 2022: $74K · 2023: $137K · 2024: $43K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $172K · Travel and Lodging: $23K · Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,875.00 |
| Travel and Lodging | $23,140.22 |
| Food and Beverage | $2,555.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320,781.60 | 2021-2025 | |
| Allergan, INC. | $156,123.90 | 2019-2021 | |
| Alkermes, INC. | $14,526.24 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10,524.57 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $8,675.98 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $743.68 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $398.11 | 2021-2025 | Caplyta |
| Sage Therapeutics, LLC | $150.63 | 2022 | |
| Janssen Pharmaceuticals, INC | $131.79 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $84.29 | 2020-2025 | Rexulti, Rejoyn |
| Lundbeck LLC | $51.26 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $24.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.96 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.